Goldman Small Cap Research Initiates Coverage on NeoStem With Buy Rating
-
FOR: BIOMEDREPORTS
Goldman Small Cap Research |
FDA Calendar and Database |
LOS ANGELES, CA--(Marketwire - July 29, 2010) - Goldman Small Cap Research, which produces free, timely, actionable, research on publicly-traded emerging growth companies has initiated coverage on NeoStem (
According to Rob Goldman, senior research analyst, NeoStem has already begun to successfully leverage its Suzhou Erye operations and we expect the Company to ride the huge wave of growth in the Chinese pharmaceuticals market. The industry is expected to triple in size by 2014 and become the 3rd largest pharmaceutical market the world.
"This undervalued company is a leader in 2 of the most exciting and fastest-growing segments of the entire health care sector," writes Goldman. "Plus, its diversified business approach lowers the risk profile as compared to other stem cell plays. Based on our sum-of-the-parts valuation, we project that the China pharma operations could be worth nearly $2.80 a share and the stem cell business worth a conservative $1.70 per share. This is based on publicly-traded generic comparables and stem cell company peer valuations. We rate the stock a Speculative Buy with a $4.50 six-month price target."
The Goldman Small Cap Research team has extensive experience in investment research and management which enables the group to produce high quality and relevant company reports, snapshots, and valuations.
A complete, complimentary report on the company is available now at GoldmanResearch.com
About Goldmam Small Cap Research:
Founder Rob Goldman has 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell-side analyst, Rob was a senior member of Piper Jaffray's Technology research team covering Israeli Technology and Communications Software. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group as well as the Firm's Israeli research team. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.
About BioMedReports.Com
BioMedReports.com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies.
For more biomedical sector and investment news, we invite readers to visit BioMedReports.com at http://BioMedReports.com
Media Contact:
Mary Davila
Assistant Editor
BioMedReports.com
e-mail: Email Contact
Tel: +1 323 472 4480
Fax: +1 888 210 3556